Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours

NCT03894540 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
22
Enrollment
INDUSTRY
Sponsor class

Stopped Following an internal portfolio review, Ipsen has made the decision to terminate study D-US-60090-001. Ipsen would like to highlight that early termination was not due to any safety or tolerability issues with IPN60090

Conditions

Interventions

Sponsor

Ipsen